NOS3 and endothelial dysfunction: Given the central role of endothelial dysfunction in CVD pathophysiology, optimizing pharmacological strategies to enhance eNOS function and NO bioavailability remains a pivotal objective in preventive and therapeutic cardiometabolic medicine.